Dublin, Ohio headquartered Navidea Biopharmaceuticals Inc's shares finished Wednesday's trading session flat at $0.87. A total volume of 116,377 shares was traded. In the previous three months, the stock has advanced 67.31%. The Company's shares are trading above their 50-day and 200-day moving averages by 16.72% and 1.58%, respectively. Moreover, shares of Navidea Biopharmaceuticals, which focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, have a Relative Strength Index (RSI) of 52.23.
On September 26th, 2016, Navidea Biopharmaceuticals announced that its Board of Directors has appointed Michael M. Goldberg, M.D. as President and CEO effective September 22nd, 2016. The Board has also appointed Eric K. Rowinsky M.D., a Navidea board member since 2010, as Chairman of its Board. See our free and comprehensive research report on NAVB at:
On Wednesday, shares in Boston, Massachusetts headquartered ZIOPHARM Oncology Inc. recorded a trading volume of 1.48 million shares, and ended the session 1.14% lower at $5.20. The stock has gained 13.04% in the previous three months. The Company's shares are trading 4.55% below their 50-day moving average. Furthermore, shares of ZIOPHARM Oncology, which focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology, have an RSI of 42.52.
On October 10th, 2016, ZIOPHARM Oncology announced the presentation of preliminary data from its Phase 1b/2 study of Ad-RTS-hIL-12 + veledimex following standard chemotherapy for the treatment of patients with locally advanced or metastatic breast cancer. The study, which is being conducted at the Memorial Sloan Kettering Cancer Center in New York, is designed to examine the safety, tolerability and efficacy of Ad-RTS-hIL-12 immunotherapy in up to 40 women with locally advanced or metastatic breast cancer of all subtypes. Ad-RTS-hIL-12 + veledimex is a novel gene therapy which controls local expression of IL-12. Results show that Ad-RTS-hIL-12 + 7 days of veledimex consistently elicited production of IL-12 which in turn produced IFNγ. ZIOP free research report PDF is just a click away at:
Shares in New York headquartered Intra-Cellular Therapies Inc. closed the day at $13.11, slightly down 0.08% from the previous session. The stock recorded a trading volume of 579,751 shares. The Company's shares are trading 61.54% below their 50-day moving average. Additionally, shares of Intra-Cellular Therapies, which discovers and develops small molecule drugs for the treatment of neuropsychiatric and neurologic disorders within the central nervous system, have an RSI of 16.98.
On September 28th, 2016, the company announced top-line results from the second Phase 3 clinical trial of ITI-007, an oral, first-in-class investigational medicine for the treatment of schizophrenia. In this trial, neither dose of ITI-007 separated from placebo on the primary endpoint, change from baseline on the Positive and Negative Syndrome Scale total score, in the pre-defined patient population. The active control, risperidone, did separate from placebo. In this trial, ITI-007 was statistically significantly better than risperidone on key safety and tolerability parameters and exhibited a safety profile similar to placebo.
On September 29th, 2016, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with a decrease of the target price from $74 a share to $49 a share. Sign up for your complimentary report on ITCI at:
At the closing bell yesterday, shares in North Carolina headquartered Cempra Inc. ended flat at $22.36 and with a total trading volume of 678,814 shares. The stock has advanced 25.41% in the previous three months. The Company's shares are trading above their 200-day moving average by 16.09%. Furthermore, shares of Cempra, which focuses on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases in North America, have an RSI of 45.08.
On October 04th, 2016, Cempra, announced the presentation of three abstracts based upon analyzing treatment failures with existing antibiotics from more than 400,000 records of patients diagnosed with community-acquired bacterial pneumonia (CABP) in a large U.S. insurance claims database. These patient records were analyzed to assess rates of failure to the most commonly prescribed antibiotics to treat CABP. This analysis showed that more than one out of five adult CABP patients failed initial antibiotic monotherapy, with the failure rate exceeding one out of four for an elderly population with certain comorbidities. Register for free on Stock-Callers.com and download the latest research report on CEMP at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA